Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06078501 · ClinicalTrials.gov registry record · Phase 3
MisOpRostol Effect on Second Trimester Abortion Blood Loss
A Phase 3 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT06078501: Clinical Trial Phase 3 study, sponsored by Stanford University.
NCT06078501 is a Phase 3 study that was terminated before completion, run by Stanford University. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06078501, a Phase 3 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
Although serious complications from second trimester abortion are rare hemorrhage is the most common cause of procedural abortion related morbidity and mortality. Misoprostol is a prostaglandin E1 analogue that is used by 75% of clinicians prior to procedural abortion for the purpose of cervical preparation. Misoprostol is also known to decrease blood loss in first trimester abortion and is used to treat postpartum hemorrhage, however the effect of preprocedural misoprostol on procedural blood loss is not well described. We will conduct a double blinded placebo-controlled gestational age stratified superiority trial of those undergoing procedural abortion between 18 and 23 weeks gestation at Stanford Health care. Participants will be randomized to either 400mcg buccal misoprostol or placebo on the day of the procedure. A quantified blood loss (QBL) will be measured during the procedure and participants will complete a survey to assess symptoms. Our primary outcome is quantified blood loss. Secondary outcomes include clinical interventions to manage excess bleeding, total procedure time, provider reported experience, patient reported experience.
Interventions
- DRUG Placebo
- DRUG Misoprostol 400mcg buccal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06078501
The ClinicalTrials.gov registry entry for NCT06078501 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06078501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06078501 about?
NCT06078501 is a clinical study titled "MisOpRostol Effect on Second Trimester Abortion Blood Loss". Although serious complications from second trimester abortion are rare hemorrhage is the most common cause of procedural abortion related morbidity and mortality. Misoprostol is a prostaglandin E1 analogue that is used by 75% of clinicians prior to procedural abortion for the purpose of cervical pre...
What is the current status of trial NCT06078501?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2024-02-08. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT06078501?
The interventions under investigation include: Placebo (DRUG), Misoprostol 400mcg buccal (DRUG).
Who is sponsoring clinical trial NCT06078501?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.